BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1008 related articles for article (PubMed ID: 28643307)

  • 1. [Application of magnetic resonance in "non-operative treatment" strategy for rectal cancer].
    Wang Y; Chen G
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Jun; 20(6):630-634. PubMed ID: 28643307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
    [No Abstract]   [Full Text] [Related]  

  • 3. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 4. [Evaluation of progression-free survival for locally advanced rectal cancer by MRI after neoadjuvant chemoradiotherapy and total mesorectal excision].
    Zhang JX; Yang Z; Fan P; Zhang JJ; Xin L; Hou LN; Du XS; Yang XT
    Zhonghua Zhong Liu Za Zhi; 2018 Feb; 40(2):121-126. PubMed ID: 29502372
    [No Abstract]   [Full Text] [Related]  

  • 5. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
    Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
    BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ["Watch and wait" strategy after neoadjuvant therapy for rectal cancer: status survey of perceptions, attitudes and treatment selection in Chinese surgeons].
    Sun TT; Wang L; Yao YF; Peng YF; Zhao J; Zhan TC; Leng JH; Wang HY; Chen N; Chen PJ; Li YJ; Zhang X; Liu XZ; Zhang Y; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):550-559. PubMed ID: 31238634
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of diffusion-weighted MRI and (18)F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review.
    Joye I; Deroose CM; Vandecaveye V; Haustermans K
    Radiother Oncol; 2014 Nov; 113(2):158-65. PubMed ID: 25483833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term prognostic analysis on complete/near-complete clinical remission for mid-low rectal cancer after neoadjuvant chemoradiotherapy].
    Wang L; Li S; Zhang X; Sun T; Du C; Chen N; Peng Y; Yao Y; Zhan T; Zhao J; Cai Y; Li Y; Wang W; Li Z; Sun Y; Ji J; Wu A
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1240-1248. PubMed ID: 30506534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognosis and complications of local excision for rectal cancer after neoadjuvant chemoradiotherapy].
    Li YH; Qiu XY; Lin GL; Zhou JL; Xiao Y; Qiu HZ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Apr; 24(4):344-351. PubMed ID: 33878824
    [No Abstract]   [Full Text] [Related]  

  • 10. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
    [No Abstract]   [Full Text] [Related]  

  • 11. Intentional Watch and Wait or Organ Preservation Surgery Following Neoadjuvant Chemoradiotherapy Plus Consolidation CAPEOX for MRI-defined Low-risk Rectal Cancer: Findings From a Prospective Phase 2 Trial (PKUCH-R01 Trial, NCT02860234).
    Wang L; Zhang XY; Zhao YM; Li SJ; Li ZW; Sun YS; Wang WH; Wu AW;
    Ann Surg; 2023 Apr; 277(4):647-654. PubMed ID: 35766394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRI Risk Stratification for Tumor Relapse in Rectal Cancer Achieving Pathological Complete Remission after Neoadjuvant Chemoradiation Therapy and Curative Resection.
    Kim H; Myoung S; Koom WS; Kim NK; Kim MJ; Ahn JB; Hur H; Lim JS
    PLoS One; 2016; 11(1):e0146235. PubMed ID: 26730717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Outcome of watch and wait strategy or organ preservation for rectal cancer following neoadjuvant chemoradiotherapy: report of 35 cases from a single cancer center].
    Wu A; Wang L; Du C; Peng Y; Yao Y; Zhao J; Zhan T; Cai Y; Li Y; Sun Y; Ji J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Apr; 20(4):417-424. PubMed ID: 28440523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Assessment of lymph node status in rectal cancer by imaging].
    Wang Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Jun; 19(6):630-3. PubMed ID: 27353097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Application value of texture analysis of magnetic resonance images in prediction of neoadjuvant chemoradiotherapy efficacy for rectal cancer].
    Shu Z; Fang S; Ding Z; Mao D; Pang P; Gong X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1051-1058. PubMed ID: 30269327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Predictive value of combination of MRI tumor regression grade and apparent diffusion coefficient for pathological complete remission after neoadjuvant treatment of locally advanced rectal cancer].
    Xu N; Huang FC; Li WL; Luan X; Jiang YM; He B
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Apr; 24(4):359-365. PubMed ID: 33878826
    [No Abstract]   [Full Text] [Related]  

  • 17. MAGNETIC RESONANCE IMAGING TO EVALUATE NEOADJUVANT THERAPY EFFECTS ON RECTAL CARCINOMA.
    Sofić A; Vukobrat-Bijedić Z; Husić-Selimović A; Šehović N; Buija D; Eminagić D; Banjin M; Đuran A
    Acta Clin Croat; 2015 Sep; 54(3):303-8. PubMed ID: 26666099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial.
    Battersby NJ; Dattani M; Rao S; Cunningham D; Tait D; Adams R; Moran BJ; Khakoo S; Tekkis P; Rasheed S; Mirnezami A; Quirke P; West NP; Nagtegaal I; Chong I; Sadanandam A; Valeri N; Thomas K; Frost M; Brown G
    Trials; 2017 Aug; 18(1):394. PubMed ID: 28851403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Value of magnetic resonance imaging in assessing the efficacy of neoadjuvant chemoradiotherapy for locally advanced rectal cancer].
    Wang Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2015 Mar; 18(3):216-20. PubMed ID: 25809322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
    Chua YJ; Barbachano Y; Cunningham D; Oates JR; Brown G; Wotherspoon A; Tait D; Massey A; Tebbutt NC; Chau I
    Lancet Oncol; 2010 Mar; 11(3):241-8. PubMed ID: 20106720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.